Abstract 216P
Background
Seminomas form around 50% of germ cell tumours of testes. It commonly occurs during third decade. It is highly chemo sensitive and radio sensitive. Those patients who recur during surveillance for early stage can be salvaged by treatment with chemotherapy or radiotherapy most of the times.
Methods
Data was collected from master case sheets of seminoma patients treated over a period of five years from January 2013 to December 2017 at department of Madras medical college, Chennai.
Results
28 patients had seminoma of testes with a median age of 37 years. All patients had classical type histopathology. Right testis was more commonly involved (n=21) than left (n=7). 4 patients had seminoma arising from undescended testes. 10.7% (n=3) patients had elevated beta hcg and 28.5% (n=8) had elevated LDH. 9 patients had stage I, 12 patients had stage II and 7 patients had stage III disease. 3 patients had trans scrotal violation at peripheral hospital. 6 patients with stage I received paraaortic nodal irradiation with a mean dose of 24Gy of which 3 patients received inguinal irradiation also. All stage II and stage III patients received adjuvant chemotherapy with BEP regimen with minimum of 3 cycles. 2.5 year DFS and OS in stage I was 88.9% (n=8) and 100% (n=9) respectively. 2.5 year DFS and OS in stage II was 83.3% (n=10) and 91.6% (n=11) respectively. 2.5 year DFS and OS was 71.4% (n=5) and 71.4% (n=5) respectively.
Conclusions
Patients presented with advanced stage compared to that given in literature due to ignorance. Treatment results were comparable with that given in the literature.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sivasubramaniam Kumaravelu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
339P - Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation: A phase III study
Presenter: Vikas Talreja
Session: e-Poster Display Session
340P - Omega-3 fatty acids for cancer cachexia in advanced non-small cell lung cancer: A meta-analysis
Presenter: Alfredo Chua
Session: e-Poster Display Session
341P - Relationship between muscle mass and quality of life in breast cancer patients who underwent chemotherapy
Presenter: Andree Kurniawan
Session: e-Poster Display Session
342P - Comparison of 0.25 mg versus 0.75 mg of palonosetron in combination with aprepitant and dexamethasone for prevention of chemotherapy-induced nausea and vomiting following cisplatin-containing chemotherapy in patients with esophageal cancer
Presenter: Satoshi Horasawa
Session: e-Poster Display Session
343P - Head-to-head comparison of palonosetron versus granisetron for prevention of chemotherapy induced nausea and vomiting: Systematic review and meta-analysis
Presenter: Chin-Hung Hsu
Session: e-Poster Display Session
344P - Single-centre analysis of anti-resorptive agent-related osteonecrosis of the jaw in lung cancer patients
Presenter: Kohei Fujita
Session: e-Poster Display Session
345P - Thromboembolic events in brain tumour patients on bevacizumab
Presenter: Gunjesh Singh
Session: e-Poster Display Session
346P - Occurence and risk factors of chemotherapy-induced neutropenia in patients with breast cancer: A hospital-based assessment in Indonesia
Presenter: Susanna Hutajulu
Session: e-Poster Display Session
347P - Histamine blockade with loratadine for prevention of granulocyte-colony stimulating factor (G-CSF)-associated bone pain: A meta-analysis
Presenter: Mel Valerie Ordinario
Session: e-Poster Display Session
348P - Anti-VEGF inhibitors and renal safety in onco-nephrology consortium: Urinary protein/creatinine ratio (VERSiON UP study)
Presenter: Michio Nakamura
Session: e-Poster Display Session